Theravance Biopharma (TBPH) Receives New Analyst Coverage with a Buy Rating

Jun 17, 2025
theravance-biopharma-(tbph)-receives-new-analyst-coverage-with-a-buy-rating

Author's Avatar

Article's Main Image

On June 17, 2025, Jones Trading initiated coverage on Theravance Biopharma (TBPH, Financial) with a favorable Buy rating. The analyst, Debanjana Chatterjee, provided a price target of USD 24.00 per share, marking a significant development for the company’s stock outlook.

Theravance Biopharma (TBPH, Financial), listed on NASDAQ, has garnered attention following this analyst coverage, potentially influencing investor sentiment and market activity. The announcement marks the commencement of analyst coverage, aiming to offer insights into the stock’s potential performance.

This new price target and rating signify the analyst’s confidence in Theravance Biopharma’s (TBPH, Financial) future prospects, suggesting a positive trajectory for the company’s shares in the market.

Wall Street Analysts Forecast

1934938840670302208.png

Based on the one-year price targets offered by 5 analysts, the average target price for Theravance Biopharma Inc (TBPH, Financial) is $17.00 with a high estimate of $24.00 and a low estimate of $10.00. The average target implies an upside of 58.14% from the current price of $10.75. More detailed estimate data can be found on the Theravance Biopharma Inc (TBPH) Forecast page.

Based on the consensus recommendation from 5 brokerage firms, Theravance Biopharma Inc’s (TBPH, Financial) average brokerage recommendation is currently 2.2, indicating “Outperform” status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Based on GuruFocus estimates, the estimated GF Value for Theravance Biopharma Inc (TBPH, Financial) in one year is $19.60, suggesting a upside of 82.33% from the current price of $10.75. GF Value is GuruFocus’ estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business’ performance. More detailed data can be found on the Theravance Biopharma Inc (TBPH) Summary page.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.

Leave a comment